Jaclyn LoPiccolo

2.3k total citations · 2 hit papers
30 papers, 1.7k citations indexed

About

Jaclyn LoPiccolo is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jaclyn LoPiccolo has authored 30 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 11 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jaclyn LoPiccolo's work include PI3K/AKT/mTOR signaling in cancer (8 papers), Lung Cancer Treatments and Mutations (7 papers) and Lung Cancer Research Studies (5 papers). Jaclyn LoPiccolo is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (8 papers), Lung Cancer Treatments and Mutations (7 papers) and Lung Cancer Research Studies (5 papers). Jaclyn LoPiccolo collaborates with scholars based in United States, Germany and Canada. Jaclyn LoPiccolo's co-authors include Phillip A. Dennis, Gideon M. Blumenthal, Wendy B. Bernstein, Joell J. Gills, Shigeru Kawabata, Courtney A. Granville, Alexander Gusev, M. Christine Hollander, Pasi A. Jänne and David C. Christiani and has published in prestigious journals such as Science, Journal of Biological Chemistry and Nature Medicine.

In The Last Decade

Jaclyn LoPiccolo

28 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations

2008 656 citations Jaclyn LoPiccolo, Gideon M. Blumenthal et al. Drug Resistance Updates profile →
Lung cancer in patients who have never smoked — an emerging disease

2024 102 citations Jaclyn LoPiccolo, Alexander Gusev et al. Nature Reviews Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jaclyn LoPiccolo United States	16	920	518	268	235	231	30	1.7k
Noel A. Warfel United States	21	1.0k 1.1×	557 1.1×	169 0.6×	375 1.6×	132 0.6×	39	1.7k
Frédéric Troalen France	20	1.3k 1.4×	648 1.3×	223 0.8×	168 0.7×	113 0.5×	52	2.2k
Shigeru Kawabata Japan	18	1.2k 1.3×	1.3k 2.6×	247 0.9×	267 1.1×	334 1.4×	46	2.3k
Shaoyu Yan United States	25	910 1.0×	595 1.1×	115 0.4×	326 1.4×	421 1.8×	39	1.9k
Adrian Keogh Switzerland	26	701 0.8×	233 0.4×	532 2.0×	221 0.9×	75 0.3×	55	1.8k
Yong Cai China	24	944 1.0×	910 1.8×	221 0.8×	147 0.6×	203 0.9×	103	2.3k
Sigurd Krieger Austria	19	687 0.7×	523 1.0×	139 0.5×	195 0.8×	147 0.6×	35	1.7k
Claudio Celeghini Italy	26	1.3k 1.4×	497 1.0×	179 0.7×	391 1.7×	106 0.5×	73	2.3k
Michèle Sabbah France	30	1.6k 1.8×	962 1.9×	142 0.5×	544 2.3×	214 0.9×	81	2.7k
Kazutaka Kurokohchi Japan	20	509 0.6×	302 0.6×	495 1.8×	130 0.6×	108 0.5×	71	1.5k

Countries citing papers authored by Jaclyn LoPiccolo

Since Specialization

Citations

This map shows the geographic impact of Jaclyn LoPiccolo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaclyn LoPiccolo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaclyn LoPiccolo more than expected).

Fields of papers citing papers by Jaclyn LoPiccolo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jaclyn LoPiccolo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaclyn LoPiccolo. The network helps show where Jaclyn LoPiccolo may publish in the future.

Co-authorship network of co-authors of Jaclyn LoPiccolo

This figure shows the co-authorship network connecting the top 25 collaborators of Jaclyn LoPiccolo. A scholar is included among the top collaborators of Jaclyn LoPiccolo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jaclyn LoPiccolo. Jaclyn LoPiccolo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Durbin, Sienna, Chia‐Yun Wu, Jaclyn LoPiccolo, et al.. (2025). Late-Onset Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy. JAMA Network Open. 8(3). e252668–e252668. 10 indexed citations

LoPiccolo, Jaclyn, Biagio Ricciuti, Arthi Sridhar, et al.. (2025). Young lung cancer: from diagnosis to survivorship. Frontiers in Oncology. 15. 1570143–1570143.

Rotow, Julia, Gaetano Rocco, William D. Travis, et al.. (2025). Outcomes with neoadjuvant chemotherapy and/or osimertinib in patients with EGFR- mutant resectable non-small cell lung cancers.. Journal of Clinical Oncology. 43(16_suppl). 8052–8052.

LoPiccolo, Jaclyn, Alexander Gusev, David C. Christiani, & Pasi A. Jänne. (2024). Lung cancer in patients who have never smoked — an emerging disease. Nature Reviews Clinical Oncology. 21(2). 121–146. 102 indexed citations breakdown →

Tzeng, Alice, Kelly Fitzgerald, Jaclyn LoPiccolo, et al.. (2023). Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study. JTO Clinical and Research Reports. 4(10). 100559–100559. 6 indexed citations

Cheng, Michael L., Jaclyn LoPiccolo, Mizuki Nishino, et al.. (2023). Exceptional Response to Bromodomain and Extraterminal Domain Inhibitor Therapy With BMS-986158 in BRD4-NUTM1 NUT Carcinoma Harboring a BRD4 Splice Site Mutation. JCO Precision Oncology. 7(7). e2200633–e2200633. 4 indexed citations

Moon, Intae, Jaclyn LoPiccolo, Sylvan C. Baca, et al.. (2023). Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary. Nature Medicine. 29(8). 2057–2067. 51 indexed citations

Odintsov, Igor, Maisam Makarem, Mizuki Nishino, et al.. (2023). Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC. Journal of Thoracic Oncology. 19(5). 732–748. 11 indexed citations

LoPiccolo, Jaclyn, Megan D. Schollenberger, Samuel Rosner, et al.. (2019). Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series. Journal for ImmunoTherapy of Cancer. 7(1). 170–170. 41 indexed citations

10.

Erami, Zahra, Bassem D. Khalil, Yanhua Yao, et al.. (2017). Rac1-stimulated macropinocytosis enhances Gβγ activation of PI3Kβ. Biochemical Journal. 474(23). 3903–3914. 18 indexed citations

11.

Shymanets, Aliaksei, Oscar Vadas, Cornelia Czupalla, et al.. (2015). Different inhibition of Gβγ-stimulated class IB phosphoinositide 3-kinase (PI3K) variants by a monoclonal antibody. Specific function of p101 as a Gβγ-dependent regulator of PI3Kγ enzymatic activity. Biochemical Journal. 469(1). 59–69. 16 indexed citations

12.

LoPiccolo, Jaclyn, Seung Joong Kim, Yi Shi, et al.. (2015). Assembly and Molecular Architecture of the Phosphoinositide 3-Kinase p85α Homodimer. Journal of Biological Chemistry. 290(51). 30390–30405. 20 indexed citations

13.

Kawabata, Shigeru, Joell J. Gills, Jaclyn LoPiccolo, et al.. (2012). Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells. Cell Death and Disease. 3(7). e353–e353. 59 indexed citations

14.

Gills, Joell J., Mones Abu‐Asab, S. Sianna Castillo, et al.. (2012). Ceramide mediates nanovesicle shedding and cell death in response to phosphatidylinositol ether lipid analogs and perifosine. Cell Death and Disease. 3(7). e340–e340. 18 indexed citations

15.

Granville, Courtney A., Regan M. Memmott, Jacopo Mariotti, et al.. (2009). A Central Role for Foxp3+ Regulatory T Cells in K-Ras-Driven Lung Tumorigenesis. PLoS ONE. 4(3). e5061–e5061. 66 indexed citations

16.

Gills, Joell J., Jaclyn LoPiccolo, & Phillip A. Dennis. (2008). Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy. Autophagy. 4(1). 107–109. 107 indexed citations

17.

LoPiccolo, Jaclyn, Gideon M. Blumenthal, Wendy B. Bernstein, & Phillip A. Dennis. (2008). Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations. Drug Resistance Updates. 11(1-2). 32–50. 656 indexed citations breakdown →

18.

Gills, Joell J., Jaclyn LoPiccolo, Junji Tsurutani, et al.. (2007). Nelfinavir, A Lead HIV Protease Inhibitor, Is a Broad-Spectrum, Anticancer Agent that Induces Endoplasmic Reticulum Stress, Autophagy, and Apoptosis In vitro and In vivo. Clinical Cancer Research. 13(17). 5183–5194. 264 indexed citations

19.

LoPiccolo, Jaclyn, Marc Ballas, & Phillip A. Dennis. (2007). PTEN hamartomatous tumor syndromes (PHTS): Rare syndromes with great relevance to common cancers and targeted drug development. Critical Reviews in Oncology/Hematology. 63(3). 203–214. 13 indexed citations

20.

LoPiccolo, Jaclyn, Courtney A. Granville, Joell J. Gills, & Phillip A. Dennis. (2007). Targeting Akt in cancer therapy. Anti-Cancer Drugs. 18(8). 861–874. 109 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact